Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

January 20, 2026

Study Completion Date

March 20, 2026

Conditions
Effect of DrugAdverse Drug EventMechanical Ventilation ComplicationCritical IllnessSurgerySedation
Interventions
DRUG

Remimazolam Besylate

patients will be sedated with remimazolam via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if remimazolam fails to achieve a satisfactory RASS score (0 to -2 points) within its upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).

DRUG

Dexmedetomidine Hydrochloride

patients will be sedated with dexmedetomidine hydrochloride via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if dexmedetomidine fails to achieve a satisfactory RASS score (0 to -2 points) within the upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).

Trial Locations (1)

100038

RECRUITING

Beijing Shijitan Hospital.CMU, Beijing

All Listed Sponsors
lead

Beijing Shijitan Hospital, Capital Medical University

OTHER